<DOC>
	<DOCNO>NCT00673335</DOCNO>
	<brief_summary>RATIONALE : Letrozole may prevent breast cancer postmenopausal woman BRCA1 BRCA2 mutation . PURPOSE : This randomized phase III trial study letrozole see well work compare placebo prevent breast cancer postmenopausal woman BRCA1 BRCA2 mutation .</brief_summary>
	<brief_title>Letrozole Preventing Breast Cancer Postmenopausal Women With BRCA1 BRCA2 Mutation</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate reduction incidence invasive breast cancer postmenopausal woman BRCA1/BRCA2 mutation treat letrozole . Secondary - Determine reduction incidence situ breast cancer woman . - Determine recurrence rate local metastatic disease woman breast cancer . - Determine incidence non-breast cancer , especially ovarian , colon , endometrial cancer . - Assess tolerance drug term lipid , cardiovascular , bone effect . - Determine quality life woman treat drug . - Identify serological marker allow early diagnosis hereditary predisposition breast cancer . - Conduct pharmacogenetic analysis . - Identify biomarkers gene involve occurrence cardiovascular rheumatologic metabolic aromatase inhibitor . - Study phenotypic characteristic cancer occur treatment letrozole , particular hormonal marker ( estrogen progesterone receptor ) expression profile resistance therapy . OUTLINE : This multicenter study . Patients stratify accord nature mutation ( BRCA1 v BRCA2 ) , oophorectomy premenopausal state ( yes v ) , prior breast cancer ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral letrozole daily . - Arm II : Patients receive oral placebo daily . Treatment arm continue 5 year absence unacceptable toxicity development cancer recurrent disease . Blood sample collect periodically pharmacogenetic study analysis biomarkers gene associate hereditary predisposition breast cancer , toxicity , resistance therapy . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must meet following criterion : With without invasive unilateral breast cancer 5 year ago , recurrence No evidence breast cancer mammography MRI within past year Carrier BRCA1/BRCA2 deleterious mutation ( nonsense mutation stop ) Refused preventive mastectomy No prior bilateral breast cancer No prior bilateral mastectomy Hormone receptor status specify PATIENT CHARACTERISTICS : Inclusion criterion : Menopausal status indicate 1 follow criterion : Age &gt; 60 year Bilateral oophorectomy Age ≤ 60 year hysterectomy amenorrhea within past 12 month Age ≤ 60 year prior hysterectomy FSH &gt; 20 IU/L Eastern Cooperative Oncology Group ( ECOG ) WHO performance status 01 absolute neutrophil count ( ANC ) &gt; 2,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 10 g/dL Bilirubin normal ALT AST &lt; 2.5 time upper limit normal Creatinine clearance ≥ 60 mL/min Adequate cardiovascular function ( e.g. , history myocardial infarction , angina pectoris , heart failure ) No osteoporosis bone density scan ( DEXA ) within past 2 year prior osteoporotic fracture ( femur , lumbar spine T score &gt; 2 DS ) Exclusion criterion : Invasive cancer diagnose past 5 year , except basal cell squamous cell skin cancer carcinoma situ cervix Prior cerebrovascular accident Prior cardiac ischemia Hypersensitivity letrozole excipients , especially titanium oxide Renal hepatocellular insufficiency , cholestasis , cytolysis Geographical , social , psychological reason preclude medical monitoring study Deprived liberty guardianship PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 month since prior concurrent hormone replacement therapy ( e.g. , thyroidstimulating hormone ) No prior hormonal therapy past year No concurrent participation another therapeutic study experimental drug</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>hereditary breast/ovarian cancer ( BRCA1 , BRCA2 )</keyword>
	<keyword>BRCA1 mutation carrier</keyword>
	<keyword>BRCA2 mutation carrier</keyword>
</DOC>